A Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic Cancer

Recruiting

Phase 1

A Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic CancerA Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic Cancer

Sponsor:

Abramson Cancer Center at Penn Medicine

Code:

NCT02207465

Conditions

Locally Advanced Unresectable Pancreatic Cancer Treated With Chemoradiotherapy

Borderline Resectable Pancreatic Cancer Treated With Chemoradiotherapy

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Radiotherapy

Abraxane

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-31. This information was provided to ClinicalTrials.gov by Abramson Cancer Center at Penn Medicine on 2024-11-07.